Previous 10 | Next 10 |
Lantheus press release ( NASDAQ: LNTH ): Q4 Non-GAAP EPS of $1.37 beats by $0.41 . Revenue of $263.16M (+103.1% Y/Y) beats by $17.83M . 1Q23 Revenue between $280M-$285M vs consensus $256.47M. Adj. EPS between $1.28-$1.32 vs consensus of $1.06 FY23 Revenue between $...
Worldwide revenue of $263.2 million and $935.1 million for the fourth quarter and full year 2022, representing increases of 103.1% and 119.9% over the prior year periods, respectively GAAP net loss of $119.2 million and GAAP net income of $28.1 million for the fourth quarter and full ye...
Lantheus ( NASDAQ: LNTH ) is scheduled to announce Q4 earnings results on Thursday, February 23rd, before market open. The consensus EPS Estimate is $0.96 (compared to $0.25 in year ago quarter) and the consensus Revenue Estimate is $245.33M (+89.3% Y/Y). Over the last 2 years...
BEDFORD, Mass., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease, tod...
Summary Investors allocating on weakness within new-year rally. Stock wedging up to previous resistance marks, testing key retracement levels. Heavy inflows into LNTH equity into the New Year as well, correlating to the rally off lows. Net-net, reiterate buy, searching for short...
Summary POINT Biopharma Global Inc. has a set of radioligand therapies in various stages. It has a major deal with Lantheus. The company has a long cash runway. POINT Biopharma Global Inc. ( PNT ) is a clinical-stage company developing radioligands targeting cancer. It...
BEDFORD, Mass., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, February 23, 2023, to discuss its financial and operating results for the fourth ...
BEDFORD, Mass., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease, ann...
Lantheus Holdings ( NASDAQ: LNTH ) on Monday said it had acquired Cerveau Technologies, a company that uses molecular imaging to help the development of therapies to treat Alzheimer's disease and other cognitive disorders. The acquisition gives LNTH access to Cerveau's lead asset MK-6...
BEDFORD, Mass., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow dise...
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
16.4%Change Percent:
Lantheus Holdings Inc. Company Name:
LNTH Stock Symbol:
NASDAQ Market:
Lantheus Holdings Inc. Website:
Second Quarter 2024 Worldwide revenue of $394.1 million, an increase of 22.5% from second quarter 2023 Completed three strategic transactions to expand innovative pipeline GAAP fully diluted earnings per share of $0.88, compared to $1.33 in second quarter 2023. Adjusted fully ...
BEDFORD, Mass., July 17, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Wednesday, July 31, 2024, to discuss its financial and operating results for the second...
BEDFORD, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced its acqu...